The Department of Defense offers the Neurofibromatosis Exploration-Hypothesis Development Award to support innovative and pioneering concepts in NF research. This grant encourages the exploration of high-risk, high-gain ideas that have the potential to revolutionize NF studies. Researchers are expected to propose well-formulated, testable hypotheses with a strong scientific basis and innovative qualities. Human subject studies are allowed but must meet specific regulatory guidelines. Clinical trials are not permitted under this award. Applicants should ensure their projects are exempt or eligible for expedited review. This funding opportunity aims to lay the foundation for future advancements in the field of Neurofibromatosis.
Opportunity ID: 256030
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-NFRP-EHDA |
| Funding Opportunity Title: | DoD Neurofibromatosis Exploration-Hypothesis Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 27, 2014 |
| Last Updated Date: | May 28, 2014 |
| Original Closing Date for Applications: | Jul 24, 2014 |
| Current Closing Date for Applications: | Jul 24, 2014 |
| Archive Date: | Aug 23, 2014 |
| Estimated Total Program Funding: | $1,280,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The NFRP Exploration – Hypothesis Development Award mechanism was first offered in FY08. Since then, 149 Exploration – Hypothesis Development Award applications have been received, and 31 have been recommended for funding.The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is encouraged, but not required.The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of NF.Research involving human subjects and human anatomical substances is permitted; however, studies must be exempt under Title 32 of the Code of Regulations, Part 219.101(b) (32 CFR 219.101(b)) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Exemption or expedited status is first determined by the Institutional Review Board (IRB) of record. Investigators must review their institutional requirements and guidelines for filing with the IRB for exempt or expedited status. Studies that do not qualify for exempt or expedited status will be administratively withdrawn. Clinical trials are not allowed under this funding opportunity. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm. PIs wishing to apply for funding for a clinical trial should utilize the FY14 NFRP Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-14-NFRP-CTA). |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Phone: 301-682-5507
Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Modification necessary to correct Estimated Total Program Funding. | May 28, 2014 | |
| May 28, 2014 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-NFRP-EHDA |
| Funding Opportunity Title: | DoD Neurofibromatosis Exploration-Hypothesis Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 27, 2014 |
| Last Updated Date: | May 28, 2014 |
| Original Closing Date for Applications: | Jul 24, 2014 |
| Current Closing Date for Applications: | Jul 24, 2014 |
| Archive Date: | Aug 23, 2014 |
| Estimated Total Program Funding: | $1,280,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The NFRP Exploration – Hypothesis Development Award mechanism was first offered in FY08. Since then, 149 Exploration – Hypothesis Development Award applications have been received, and 31 have been recommended for funding.The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is encouraged, but not required.The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of NF.Research involving human subjects and human anatomical substances is permitted; however, studies must be exempt under Title 32 of the Code of Regulations, Part 219.101(b) (32 CFR 219.101(b)) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Exemption or expedited status is first determined by the Institutional Review Board (IRB) of record. Investigators must review their institutional requirements and guidelines for filing with the IRB for exempt or expedited status. Studies that do not qualify for exempt or expedited status will be administratively withdrawn. Clinical trials are not allowed under this funding opportunity. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm. PIs wishing to apply for funding for a clinical trial should utilize the FY14 NFRP Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-14-NFRP-CTA). |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Phone: 301-682-5507
Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-NFRP-EHDA |
| Funding Opportunity Title: | DoD Neurofibromatosis Exploration-Hypothesis Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 28, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jul 24, 2014 |
| Archive Date: | Aug 23, 2014 |
| Estimated Total Program Funding: | $1,028,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The NFRP Exploration – Hypothesis Development Award mechanism was first offered in FY08. Since then, 149 Exploration – Hypothesis Development Award applications have been received, and 31 have been recommended for funding.
The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is encouraged, but not required. The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of NF. Research involving human subjects and human anatomical substances is permitted; however, studies must be exempt under Title 32 of the Code of Regulations, Part 219.101(b) (32 CFR 219.101(b)) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Exemption or expedited status is first determined by the Institutional Review Board (IRB) of record. Investigators must review their institutional requirements and guidelines for filing with the IRB for exempt or expedited status. Studies that do not qualify for exempt or expedited status will be administratively withdrawn. Clinical trials are not allowed under this funding opportunity. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm. PIs wishing to apply for funding for a clinical trial should utilize the FY14 NFRP Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-14-NFRP-CTA). |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Phone: 301-682-5507
Email: help@eBRAP.org Email:help@eBRAP.org |
Related Documents
Folder 256030 Full Announcement-1 -> NFRP_FY14 EHDA PA_GG.pdf
Packages
| Agency Contact Information: | Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00197420 | May 27, 2014 | Jul 24, 2014 | View |
Package 1
Mandatory forms
256030 RR_SF424_2_0-2.0.pdf
256030 RR_Budget_1_3-1.3.pdf
256030 RR_KeyPersonExpanded_2_0-2.0.pdf
256030 PerformanceSite_2_0-2.0.pdf
Optional forms
256030 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
